142 related articles for article (PubMed ID: 23010853)
1. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
Devriese LA; Witteveen PO; Marchetti S; Mergui-Roelvink M; Reyderman L; Wanders J; Jenner A; Edwards G; Beijnen JH; Voest EE; Schellens JH
Cancer Chemother Pharmacol; 2012 Dec; 70(6):823-32. PubMed ID: 23010853
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.
Tan AR; Sarantopoulos J; Lee L; Reyderman L; He Y; Olivo M; Goel S
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1051-61. PubMed ID: 26433580
[TBL] [Abstract][Full Text] [Related]
3. Eribulin mesylate in patients with refractory cancers: a Phase I study.
Mukohara T; Nagai S; Mukai H; Namiki M; Minami H
Invest New Drugs; 2012 Oct; 30(5):1926-33. PubMed ID: 21887501
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
Tan AR; Rubin EH; Walton DC; Shuster DE; Wong YN; Fang F; Ashworth S; Rosen LS
Clin Cancer Res; 2009 Jun; 15(12):4213-9. PubMed ID: 19509146
[TBL] [Abstract][Full Text] [Related]
6. Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305.
Macpherson IR; He Y; Palmieri C
Breast Cancer Res; 2021 Mar; 23(1):33. PubMed ID: 33736675
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
Devriese LA; Witteveen PE; Wanders J; Law K; Edwards G; Reyderman L; Copalu W; Peng F; Marchetti S; Beijnen JH; Huitema AD; Voest EE; Schellens JH
Br J Clin Pharmacol; 2013 Feb; 75(2):507-15. PubMed ID: 22803519
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.
Mukai H; Saeki T; Shimada K; Naito Y; Matsubara N; Nakanishi T; Obaishi H; Namiki M; Sasaki Y
Invest New Drugs; 2015 Feb; 33(1):119-27. PubMed ID: 25242374
[TBL] [Abstract][Full Text] [Related]
11. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E; Klaar S; Berglund EG; Salmonson T; Borregaard J; Hofland KF; Ersbøll J; Abadie E; Giuliani R; Pignatti F
Clin Cancer Res; 2012 Sep; 18(17):4491-7. PubMed ID: 22829199
[TBL] [Abstract][Full Text] [Related]
12. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.
Devriese LA; Mergui-Roelvink M; Wanders J; Jenner A; Edwards G; Reyderman L; Copalu W; Peng F; Marchetti S; Beijnen JH; Schellens JH
Invest New Drugs; 2013 Apr; 31(2):381-9. PubMed ID: 22555773
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
Evans TRJ; Dean E; Molife LR; Lopez J; Ranson M; El-Khouly F; Zubairi I; Savulsky C; Reyderman L; Jia Y; Sweeting L; Greystoke A; Barriuso J; Kristeleit R
Br J Cancer; 2019 Feb; 120(4):379-386. PubMed ID: 30679780
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
Koczywas M; Frankel PH; Synold TW; Lenz HJ; Mortimer JE; El-Khoueiry AB; Gandara DR; Cristea MC; Chung VM; Lim D; Reckamp KL; Lau DH; Doyle LA; Ruel C; Carroll MI; Newman EM
Br J Cancer; 2014 Dec; 111(12):2268-74. PubMed ID: 25349975
[TBL] [Abstract][Full Text] [Related]
15. Eribulin: rediscovering tubulin as an anticancer target.
Jimeno A
Clin Cancer Res; 2009 Jun; 15(12):3903-5. PubMed ID: 19509144
[TBL] [Abstract][Full Text] [Related]
16. A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
Twelves C; Anthoney A; Savulsky CI; Guo M; Reyderman L; Cresti N; Semiglazov V; Timcheva C; Zubairi I; Morrison R; Plummer R; Evans TRJ
Br J Cancer; 2019 Mar; 120(6):579-586. PubMed ID: 30783204
[TBL] [Abstract][Full Text] [Related]
17. A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.
Lesimple T; Edeline J; Carrothers TJ; Cvitkovic F; Darpo B; Delord JP; Léna H; Penel N; Edwards GJ; Law K; Wanders J; Kristensen A; Reyderman L
Invest New Drugs; 2013 Aug; 31(4):900-9. PubMed ID: 23143778
[TBL] [Abstract][Full Text] [Related]
18. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
[TBL] [Abstract][Full Text] [Related]
19. [Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer].
Koyama N; Tokunaga T; Ogasawara W; Murakami M; Yamashita Y
Nihon Yakurigaku Zasshi; 2011 Nov; 138(5):209-17. PubMed ID: 22075465
[No Abstract] [Full Text] [Related]
20. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
